Staging and therapy of cutaneous melanoma patients with sentinel lymph node (SLN) biopsies and the use of systemic adjuvant therapy in those with high risk primaries and/or regional lymph node metastases lately have become commonplace, although neither has been shown unequivocally to improve survival. It is both timely and important to develop prognostic models that have potential utility for the design of efficient clinical trials and for clinical management of patients with melanoma. The objective of this project is to develop prognostic models using a rigorously documented and carefully followed cohort of over 5,500 melanoma patients assembled since 1972 and an archive of tissue blocks containing a representative sample of their primary lesions. The application of novel biostatistical methods using clinical and new immunohistologic data will allow us to achieve our explicit goals. To protect patients with """"""""minimal risk"""""""" melanomas from the morbidity and cost of excessive investigation and therapy, in the first specific aim we will test the hypothesis that invasive melanoma without metastatic capacity can be identified using currently available, easily employed, and readily interpreted clinical, histologic and immunohistologic prognostic variables. To better calibrate investigation and management of patients with metastatic capacity by clinical trialists and clinicians, in the second specific aim we will develop multivariable prognostic models for predicting the likelihood of a SLN biopsy revealing melanoma and of metastasis-free survival after regional surgical staging and therapy. To optimize surveillance for additional primary melanomas in follow-up, in the third specific aim we will develop multivariable prognostic models for predicting the occurrence or a second primary. To promote the use of these models by clinical trialists and clinicians, we will develop individualized patient probabilities of the occurrence of clinically relevant events that can be used in trial design and clinical decision making.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA093372-01
Application #
6543521
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-28
Project End
2003-09-27
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Nti, Akosua A; Serrano, Leona W; Sandhu, Harpal S et al. (2018) FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina :
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garman, Bradley; Anastopoulos, Ioannis N; Krepler, Clemens et al. (2017) Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep 21:1936-1952
Rebecca, Vito W; Nicastri, Michael C; McLaughlin, Noel et al. (2017) A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discov 7:1266-1283
Ndoye, Abibatou; Budina-Kolomets, Anna; Kugel 3rd, Curtis H et al. (2017) ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Res 77:5873-5885
Taylor, Laura A; Abraham, Ronnie M; Tahirovic, Emin et al. (2017) High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Mod Pathol 30:634-639

Showing the most recent 10 out of 106 publications